BioMérieux snags BioFire Diagnostics in $450M buy

French diagnostics developer bioMérieux is ponying up $450 million for the newly renamed BioFire Diagnostics in a move that helps consolidate its position in infectious disease testing. Chairman and CEO Jean-Luc Bélingard envisions using BioFire's Salt Lake City, UT, headquarters and 500-plus employees as foundations for growth in molecular diagnostics. Story

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.